Jefferies keeps Buy ratings on six healthcare stocks
In short
Jefferies kept Buy ratings on six healthcare companies while hospital stocks were falling. The summary says the stock losses were linked to regulatory scrutiny over cancer-drug markups and pharmacy practices, and that upside targets range from 22% to 46%.
This matters because investors are weighing analyst optimism against the sector selloff. The six companies are not named in the available reporting.
What the reporting says
Jefferies maintained Buy ratings on six healthcare companies as hospital stocks extended losses amid regulatory scrutiny over cancer-drug markups and pharmacy practices. The broker cited target-price upside of 22% to 46% and strong projected EBITDA growth through FY29, but the available summary does not name the six stocks. The immediate effect is continued analyst support despite sector weakness and unresolved regulatory pressure.
Why it matters
The publisher summary says hospital stocks extended losses because of regulatory scrutiny over cancer-drug markups and pharmacy practices. Jefferies still kept Buy ratings on six healthcare companies, pointing to upside of 22% to 46% and strong projected EBITDA growth through FY29. The reporting supports a positive analyst stance, but it does not name the companies or explain the regulatory action in detail.